ADA 2026: The Multi-Agonist and Oral Incretin Readouts, Summarized
ADA 2026 delivered phase 3 data on a triple GLP-1/GIP/glucagon agonist, a dual agonist, CagriSema and two oral agents. Here is the map.
Tagged
glp-1
7 notes in this topic
FDA’s 2026 Move to Bar Bulk Compounding of GLP-1 Drugs: What It Means for Research Suppliers
In 2026 FDA moved to end bulk compounding of GLP-1 drugs and began citing research-labeled sellers of the same peptides. The two stories are one story.
Triple GLP-1/GIP/Glucagon Agonists: Where the Research Stands
How a single peptide came to activate three proglucagon-family receptors, what phase 2 trials of the class reported, and what is still unknown.
What Are GLP-1 Peptides? Incretin Biology for Researchers
The biology behind GLP-1: where it comes from, what it does, why the native hormone lasts two minutes, and how synthetic analogues were built to last a week.
GLP-1 vs. GIP vs. Glucagon Receptors: Why Multi-Agonism Emerged
Three related receptors, three different jobs. How the biology of GLP-1, GIP and glucagon receptors led from selective agonists to dual and triple agonists.
Semaglutide vs. Tirzepatide: Single vs. Dual Agonism in the Literature
What the SUSTAIN, STEP, SURPASS and SURMOUNT programs show about a GLP-1 agonist and a GLP-1/GIP dual agonist, and what the comparison does and does not settle.
Neuroprotective Peptides: An Overview of the Research Landscape
A map of the peptide classes studied for neuroprotection, melanocortin fragments, incretins, neurotrophin mimetics, mitochondrial peptides, and how each fared.
All content in the research library is educational and intended for qualified researchers. Products referenced are for laboratory research use only and are not approved for human or veterinary use. Nothing here is medical advice.